Precision Biosciences (DTIL) Operating Income (2018 - 2026)

Precision Biosciences (DTIL) has 9 years of Operating Income data on file, last reported at -$9.1 million in Q1 2026.

• On a quarterly basis, Operating Income rose 58.96% year-over-year to -$9.1 million in Q1 2026; TTM through Mar 2026 was -$39.1 million, a 11.29% increase from a year earlier, with the FY2025 full-year figure at -$52.1 million, down 99.33% from the prior year.
• Operating Income for Q1 2026 stood at -$9.1 million, down from $12.5 million in the prior quarter.
• Over the last five years, Operating Income for DTIL reached as high as $24.1 million in Q2 2024 and fell as low as -$29.6 million in Q2 2022.
• Historically, Operating Income has averaged -$12.6 million across 5 years, with a median of -$14.7 million in 2022.
• Across the five-year window, Operating Income soared 871.68% in 2024 and slumped 428.11% in 2025, its largest moves.
• Year by year, Operating Income stood at -$12.1 million in 2022, then declined by 22.97% to -$14.9 million in 2023, then slumped by 66.86% to -$24.8 million in 2024, then soared by 150.34% to $12.5 million in 2025, then plunged by 172.55% to -$9.1 million in 2026.
• Per Business Quant data, the three most recent Operating Income figures were -$9.1 million in Q1 2026, $12.5 million in Q4 2025, and -$20.7 million in Q3 2025.